Kardigan, Inc.
No SEC Form 4 filings for $KARD in the last 30 days.
See all $KARD insider activity →Baird initiated coverage on Kardigan Inc (NASDAQ:KARD) with an Outperform rating and a $43 price target, citing its precision-cardiology portfolio. The stock is near its 52-week low of $12.23. Analysts highlight danicamtiv's potential and other pipeline programs. Kardigan has a Strong Buy consensus rating with targets ranging from $25 to $46. The company expects Phase 2 readouts in early 2027.
William Blair initiated coverage on Kardigan Inc (NASDAQ:KARD) with an Outperform rating and a $38 price target, citing potential upside of 174%. The firm highlighted the company's cardiovascular pipeline and experienced team. UBS also initiated coverage with a Buy rating and a $25 target. Kardigan's stock currently trades at $13.88, with Phase II readouts expected in 2027.
UBS initiates coverage of Kardigan, Inc. with a Buy rating and a $25 price target. The stock has a 5-day change of +3.31% and a 1st Jan change of -0.81%. Kardigan also announced board and committee changes effective September 29, 2026.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning KARD (Kardigan, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent KARD coverage spans financial news, insider activity and corporate actions.
New sell-side initiation frames upside optionality around multiple Phase 2 programs, but it is not a new clinical or regulatory datapoint.
Analyst initiation and a high price target suggest potential upside, likely prompting buying interest.
UBS initiates coverage of Kardigan, Inc. with a Buy rating and a $25 price target. The stock has a 5-day change of +3.31% and a 1st Jan change of -0.81%. Kardigan also announced board and committee changes effective September 29, 2026.
Board change may be viewed as a modest positive for governance but unlikely to move the stock materially.
The filing updates funding runway and advances multiple late-stage cardiovascular programs, setting near-term catalysts for 2027 readouts.
AlphAI scores every news story that mentions KARD with an AI model for sentiment and relevance, and aggregates insider trades from Kardigan, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Baird initiated coverage on Kardigan Inc (NASDAQ:KARD) with an Outperform rating and a $43 price target, citing its precision-cardiology portfolio. The stock is near its 52-week low of $12.23. Analysts highlight danicamtiv's potential and other pipeline programs. Kardigan has a Strong Buy consensus rating with targets ranging from $25 to $46. The company expects Phase 2 readouts in early 2027.
4 min readWilliam Blair initiated coverage on Kardigan Inc (NASDAQ:KARD) with an Outperform rating and a $38 price target, citing potential upside of 174%. The firm highlighted the company's cardiovascular pipeline and experienced team. UBS also initiated coverage with a Buy rating and a $25 target. Kardigan's stock currently trades at $13.88, with Phase II readouts expected in 2027.
2 min readUBS initiates coverage of Kardigan, Inc. with a Buy rating and a $25 price target. The stock has a 5-day change of +3.31% and a 1st Jan change of -0.81%. Kardigan also announced board and committee changes effective September 29, 2026.
1 min readKardigan, Inc. (KARD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 PRESS RELEASE Kardigan Announces Appointment of Kristin Reinke to its Board of Directors SOUTH SAN FRANCISCO, Calif., and PRINCETON, N.J., September 30, 2026 — Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan”), a precision cardiovascular company, announced today the appoin
1 min readKardigan, Inc. (KARD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRESS RELEASE Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates Continued to advance the development of three late-stage programs, supported by the Prolaio platform, aimed at addressing cardiovascular diseases where no approved treatm
6 min readHRTG GPE, LLC purchased 3,125,000 indirectly-held shares of Kardigan, Inc. (KARD) at $16.00 ($50.00M total) on 2026-06-22.
2 min readBERNS PAUL L purchased 1,250,000 indirectly-held shares of Kardigan, Inc. (KARD) at $16.00 ($20.00M total) on 2026-06-22.
2 min readARCH Venture Partners XIII, LLC purchased 1,250,000 indirectly-held shares of Kardigan, Inc. (KARD) at $16.00 ($20.00M total) on 2026-06-22.
2 min read